Skip to main content

Amneal to Participate at Upcoming Investor Conference

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer, will participate in the following investor conference.

Barclays 26th Annual Global Healthcare Conference

March 13, 2024

Miami, FL

Fireside chat – 8:30 AM ET

One-on-one meetings to follow

A live webcast of the presentation will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Amneal

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.96
+2.22 (1.05%)
AAPL  254.55
+1.73 (0.68%)
AMD  197.98
+1.40 (0.71%)
BAC  47.70
+0.64 (1.37%)
GOOG  305.68
+1.26 (0.41%)
META  631.26
+3.81 (0.61%)
MSFT  401.00
+1.05 (0.26%)
NVDA  182.47
-0.75 (-0.41%)
ORCL  157.24
+1.27 (0.81%)
TSLA  397.52
+1.96 (0.50%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.